Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in terms of overall survival (OS) and a higher objective response rate (ORR) and better progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC). A good liver function and Barcelona Clinic Liver Cancer (BCLC) intermediate stage were th...
Alternative Titles
Full title
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7acc8a7b4d504492b028c6fe37b86c9a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7acc8a7b4d504492b028c6fe37b86c9a
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph14010036
